Cosmos Health Inc (COSM)

In the past six months, Cosmos Health, Inc. (COSM) stock has experienced several notable events. The stock price increased by 138.25% over the last three months and 17.22% in the past month, as of November 2025. The company reported record Q3 2025 results, with revenue up 38% to $17.11 million, gross profit up 116% to $2.60 million, and a record gross margin of 15.21%. Adjusted EBITDA also improved by 74%, and the cash position rose significantly. Cosmos Health secured a $300 million financing facility to launch an Ethereum treasury strategy and has expanded its Ethereum holdings, with total investment reaching $2 million by October 2025. The company also regained compliance with Nasdaq's minimum bid price requirement, having received a 180-day extension until November 3, 2025, to meet this condition. Insider buying by CEO Grigorios Siokas has also been reported, with significant purchases of company stock. In April 2024, Nasdaq issued a notification to Cosmos Health for failing to submit its Annual Report on Form 10-K for the fiscal year ending December 31, 2023, on time, which could have impacted investor sentiment and stock volatility.

Specific information regarding the demand seasonality for Cosmos Health, Inc.'s products and services was not explicitly found in the search results. However, the broader U.S. nutraceuticals market, which Cosmos Health has entered, is driven by rising health awareness and increasing consumer interest in natural wellness solutions, immunity, gut health, cognition, and energy. This suggests a generally consistent demand influenced by health trends rather than strict seasonal patterns. While stock seasonality data indicates that May has the highest probability of a positive return for COSM stock (80%) and March the lowest (30%), this reflects stock performance rather than direct product demand seasonality. The company's strategic approach involves evaluating product availability, pricing, and demand trends to maximize performance, indicating an awareness of market dynamics.

Cosmos Health, Inc. is a diversified, vertically integrated global healthcare group headquartered in Chicago, Illinois, USA, with its initial operations established in Thessaloniki, Greece, in 2009. The company operates within the healthcare sector, specifically in the pharmaceutical and nutraceutical industries, with a focus on wholesale distribution. Cosmos Health's major products include a broad line of branded generics and over-the-counter (OTC) medications. They also develop and market their own proprietary nutraceuticals (dietary supplements) under the "Sky Premium Life" and "Mediterranation" brand names. Additionally, the company offers medical devices, baby products, branded biocides, and antiseptic soaps. The company is also involved in research and development (R&D) of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products, including R&D partnerships targeting major health disorders like obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies.

Cosmos Health, Inc. has a global geographic footprint, with operations and distribution across Europe, Asia, and North America. Specifically, the company manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the Cayman Islands, and Cyprus. Its subsidiaries in the EU and UK serve retail pharmacies and wholesale distributors. The company maintains offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. Its corporate headquarters are located in Chicago, Illinois, USA. Cosmos Health has also commenced U.S. operations with the launch of its Sky Premium Life brand, with products manufactured locally in GMP-certified, FDA-registered U.S. facilities. The company has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA.

Cosmos Health, Inc.'s brand reputation in the past year has been influenced by both positive developments and compliance challenges. The company has a news sentiment score of 1.49. A notable event that could have negatively affected its reputation was the notification from Nasdaq in April 2024 regarding the company's failure to timely submit its Annual Report on Form 10-K for the fiscal year ending December 31, 2023. This compliance issue could raise concerns among investors and the public regarding the company's operational diligence. However, the company has also announced positive developments such as record Q3 2025 results, expansion into the U.S. nutraceuticals market with its Sky Premium Life brand, and advancements in R&D, which could contribute positively to its reputation.

The ownership structure of Cosmos Health, Inc. (COSM) is characterized by a significant insider position and a high percentage of shares held by retail investors. CEO Grigorios Siokas is the largest individual shareholder, owning approximately 18.28% to 19.86% of the company's shares. Other key insiders include Georgios Terzis (CFO) and Nikolaos Bardakis (COO). Major institutional owners and shareholders include BlackRock, Inc., Vanguard Group Inc, Citadel Advisors Llc, Geode Capital Management, Llc, Renaissance Technologies Llc, XTX Topco Ltd, and State Street Corp. Institutional investors hold approximately 3.48% to 12.61% of the stock. Retail investors hold the largest segment of shares, accounting for about 75.65% of the company.